#1
1 Like
#2

Mike took 1 mg a day, every day, for some time, felt worse, had worse RHR, then quit it, lol. Looks like he did no research of how people are taking it now, before taking it.

How about weekly or bi-weekly dosing instead?

4 Likes
#3

ML is very reluctant to take any drug or supplement. He’s trying to accomplish everything through diet and exercise, which in itself is a commendable approach. However it sometimes feels like he became a bit hyperfocused on this approach, and subsequently he’s neglected the potential of drugs and supplements. Which also may result in inadequate research into these, as he’s shied away from them for so long. It’s surprising that he didn’t do more research before embarking on rapamycin, and then once he did, he didn’t try to adjust, instead immediately dropped it. It appears that his approach failed as a result of blind spots, which to be fair, all of us have.

6 Likes
#4

Mike orders everything in pure powdered form because he doesn’t want the extra things in tablets.
What’s increasing longevity and what’s OCD?

In a few years we have AI systems that will be smarter than humans, and there will be billions of these online and doing research, and people do stuff like this. As well we will have physical robots, of course.

Preparing for this scenario seem more important than longevity maximizing past every threshold of diminishing returns (and diminishing faster than you can reach them).

2 Likes
#5

Roughly, agreed. I’m however slightly less optimistic about the speed of development of useful AI, and have seen, to date, zero indication of any revolutionary breakthrough in the technology. We’re still operating with models from the 50’s and algorithmic approches from the 70’s. We have vastly more computing power, but so what, the old GIGO still applies. That said, no need to wait for more advanced AI, or GAI, with machine learning and current computational capabilities, drug discovery, image diagnostics, data mining will already accellerate medical progress significantly. We have the tools already, the problem is adoption - the older generation of establishment that is frozen in the previous culture needs to die out. Progress is always slower than it should be possible. Hopefully it won’t be too late for life extension fans in their 30’s and 40’s - I’m afraid folks like me, 60’s and up will miss the boat by just a smidgen, but such is life.

2 Likes
#6

The models have already improved ~20x the last couple of years, so just map the same improvement forward, and no there hasn’t been any ‘wall’ on the smooth exponential curve. If you look at prediction markets they will be about as smart as humans by 2030 and much smarter by 2031. Just try Claude at claude.ai, then imagine it is a few times smarter than that in a few years, and maybe 20 times smarter in +1 year past that, 40 times +2 years after that, and so on, from today. Test-time compute (generating reasoning tokens) has its own scaling laws as well.

Data is synthesized with more of the data that we want to train models on and less of the bad data and with SME (subject-matter experts) to check it a bit, like more reasoning data, that, more compute, it’s all going to have an effect.

1 Like
#7

Attia etal talked about this recently. Boosting immune function could be most beneficial aspect of Rapamycin.

3 Likes
#8

Yes tamping down chronic sterile infammation - something we all eventially get as we age - but can lower that issue with rapamycin. According to my inflammation bio-markers - my inflammation is way down to that of someone 45 years. I am almost 67.

2 Likes